• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·PHRX
Share

Pharmagen, Inc. Stocks

$ 0Last Updated 28.07.2026

Issuer Rating

Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 5171

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Pharmagen, Inc., a pharmaceutical company located in Silver Spring, Maryland, operates primarily as a distributor within the U.S. healthcare market. It provides a diverse range of specialty drugs to various medical clients, including hospitals, acute care centers, surgical facilities, and other healthcare practitioners nationwide. The company's offerings encompass sourcing and distributing specialty pharmaceuticals, blood plasma derivatives, unique medical products, vaccines, anti-infectives, and often hard-to-find medications. A key area of its expertise lies in plasma derivatives, which are vital for managing severe conditions such as cancer, hemophilia, rheumatoid arthritis, multiple sclerosis, blood disorders, hepatitis, and HIV. Additionally, Pharmagen supplies specialized products designed to treat respiratory, oncological, cardiovascular, and hormonal ailments. Beyond its core distribution activities, Pharmagen also produces and sells its own health supplements, notably Clotamin, an over-the-counter multivitamin formulated specifically for individuals undergoing Warfarin therapy. The company further serves its existing customers by supplying traditional pharmaceuticals, including a variety of antibiotics, vaccines, and other oral and injectable medicines. With a specialized focus on drug formulation, Pharmagen Inc. adopted its current name in January 2013, having previously operated as Sunpeaks Ventures, Inc.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

02.08.2026 21:00

CXMT's 466% Debut, Shein's Losses, and Trump's Son's Investments: The Top IPO Stories as of August 2

02.08.2026 18:01

AI Agents vs. Marketplaces: Who Is Morgan Stanley Backing in This Battle?

02.08.2026 02:30

An explosion occurred near a restaurant in central Moscow; there are fatalities

01.08.2026 16:01

Small caps last week: Cathie Wood’s Scribe bet, deals to acquire Forte Bio and CBIZ

01.08.2026 13:01

Apple's Short-Lived Triumph, Non-Banks Battle for Colombia, and a Dinosaur Worth Millions of Dollars

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026